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Dr Shaf Keshavjee (Toronto, Ontario, Canada). Dan, congrat-
ulations on an excellent presentation. I would like to congratulate
your whole group. Certainly Joel Cooper and Alec Patterson have
led the world in making lung transplantation a clinical reality.
What you have demonstrated is that lung transplantation can be
made a more routine operation, and you’ve provided a benchmark
in your results.
You talked about the incidence of PGD and its effect on chronic
graft dysfunction or BOS. Did you actually look at the grades of
PGD? Is it just the grade 3 PGDs that give you the poorer long-
term outcome or is it any PGD?
Dr Kreisel. There were 2 articles published from our institution
over the last few years, one by Daud and colleagues a few years
back in which he showed that all grades of PGD immediately post-
operatively were independent risk factors for the development of
BOS, and Huang and colleagues recently followed up in an article
published in the American Journal of Transplantation in which he
showed that all grades of PGD at 24, 48, and 72 hours postopera-
tively were independent risk factors for the development of BOS.
So at least in our institution, all grades seemed to correlate with the
development of late graft dysfunction.
Dr Keshavjee. I think that is an important point, because one of
the concepts that has emerged in recent years is our understanding
that late graft dysfunction is not just allograft rejection, but a mul-
tifactorial process that relates to the early events as well.
My second question, you mentioned your experience with DCD
lungs and the fact that the incidence of severe grade 3 PGD was
35%, or twice that in your brain-dead donor lungs. Currently,
many people in the field have gone so far as to say that DCD lungs
are equivalent donor lungs, or some even say that they are superior
to brain-dead donor lungs. What have you learned from your expe-
rience that you can share with us in terms of what you define as
a high-risk DCD lung?
Dr Kreisel. I don’t have a great answer for this. Our series that
we published last year included only 11 or 14 DCD donors with
a high incidence of PGD, and I don’t have the data on whether
the ischemic times were very long or whether there were any other
factors, and I know that other studies do not mirror this experience.
I think that as we accumulate more numbers, we may get a better
idea. But along the same lines, there are many events in the donor,
except for the DCD aspect, that we just don’t understand what
predicts the development of PGD, and there is a lot of work to
be done there. So I think it was just a small series, and I don’t
know whether it’s reflective of what we will see in the future.
DrKeshavjee. The introduction of the lung allocation score cer-
tainly has affected your program and changed the type of patients
who undergo transplantation. The indication for transplant diagno-
sis has shifted from predominantly emphysema to more idiopathic
pulmonary fibrosis and higher scoring patients, but I was surprisedrdiovascular Surgery c Volume 141, Number 1 221
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Xto see that it hasn’t affected your waiting time, with your waiting
time still being more than 1.5 years. I thought that the system
was going to help to sort that out in the United States. Do you
have any insights as to why it has not affected your program?
Dr Kreisel. It has affected the program. The mean waiting time
decreased from in excess of 600 days to 550 days, but why it is sig-
nificantly longer than, for example, what you experience, I don’t
have an answer for that.
Dr Keshavjee.Well, just for the information of the audience, in
the United States the waiting time varies from less than 1 month to
more than 1.5 years across the country, so it does reflect that we
haven’t totally fixed the problem with the lung allocation score.
Dr Raphael Bueno (Boston, Mass). You demonstrated that
there are different overall survivals based on the era, there was
a difference in the survival between a double and a single lung,
and there was a change when you moved more to double lungs,
if I recall. Did you take that into consideration when you showed
a difference in survival? You showed a 10-year follow up as op-
posed to a 15-year follow-up on that slide.
Dr Kreisel. I’m afraid I don’t understand your question.
Dr Bueno. Was there any time bias that could have explained
some of the differences you saw in this particular series in the sur-
vival long range between a double and a single lung transplant?
DrKreisel.No. I think the survival difference between bilateral
and single lung transplantation for emphysema and fibrosis is seen
by virtually all centers, and the centers that do not do bilateral trans-
plants do it according to availability of donor organs. So we have
seen a consistently better survival with bilateral lung transplants
than with single lung transplants, and I know of studies from
Duke and Toronto in which bilateral lung transplants were also cor-
related with lower incidence of BOS, which may provide an expla-
nation in addition to just having larger lungmass and lung capacity.
Dr Dirk Van Raemdonck (Leuven, Belgium). I’m interested in
knowing your strategies and techniques for extracorporeal support
if needed during transplantation. Has that changed over the years?
Dr Kreisel. You mean implementation of extracorporeal
membrane oxygenation if..
Dr Shrager. The use of bypass.
Dr Kreisel.We do not use elective bypass. The implementation
of cardiopulmonary bypass is either done on the basis of parame-
ters during the implantation or on preoperative parameters, but
there is no planned use of cardiopulmonary bypass at our center.
Dr Van Raemdonck. And are you using central cannulation or
peripheral?
Dr Kreisel. Central cannulation.
Dr Stephen Cassivi (Rochester, Minn). Dan, this is excellent.
You are part of a great team, obviously. I have 2 questions.
One, with regard to the PGD, you were stating in your presen-
tation that it has an effect on long-term and you showed us a curve.
What I saw was that the curve drops early, as we would expect, but
the curve later on is parallel. I don’t know whether that long-term
survival is just because they have such poor short-term survival.
Did you do anything to statistically show that after that, the condi-
tional survival is worse?
DrKreisel. I don’t think we did that analysis, but what I can tell
you is that at least in the experimental setting we have evidence
that those early events alter the adaptive immune response, and222 The Journal of Thoracic and Cardiovascular Surgthe adaptive immune response is changed at late time points in an-
imal models based on early PGD due to some interplay between
innate and adaptive immune responses. So I don’t think it’s just
a matter of the early mortality as to why we see late failure in pa-
tients who had PGD. I think there is obviously an early drop-off.
Dr Cassivi. I think you’re right, and intuitively we would think
that’s the same, but it might be interesting to look at the conditional
survival.
My second question is with regard to the lung allocation score
and how that has changed, and we see the drop-off at your institu-
tion, just like at ours and others, in thosewith COPD and how there
is a preference for the diseases other than COPD. In the recent his-
tory, have you noticed an increase in your wait-list mortality for the
patients with COPD?
Dr Kreisel. I don’t have the data. I do not think we have had an
increased mortality for patients with COPD, but I don’t have that
data.
Dr Daniel Mason (Cleveland, Ohio). I was a little surprised
that among 1000 transplants, only 20 were retransplants, and I
think only a handful of those were for BOS, and obviously there
is a lot of BOS out there. I was just curious about the Washington
University philosophy on retransplant and who is a candidate for
retransplant.
Dr Kreisel. Well, we list the patients with BOS for retrans-
plants. Why the number is so low, I don’t know. Recently we
started doing some photopheresis for BOS with some mild
improvement in outcomes, but I guess..
Dr Sugarbaker. The question is who would you consider for
a retransplant given the higher operative mortality and the lower
overall survival? Are all patients considered for retransplant
should they have graft failure early? How far out do you let
them go? Are there any issues around that that you could eluci-
date?
DrKreisel. I don’t know exactly why we haven’t done more re-
transplants. We certainly have a lot of patients with BOS listed for
retransplants. I don’t have an answer as to why the number has
been relatively low.
Dr Marcelo Cypel (Toronto, Ontario, Canada). Dan, that was
a nice presentation.
Do you have any numbers on PGD3 requiring extracorporeal
membrane oxygenation, and what were the outcomes of those
patients who underwent..
Dr Kreisel. I don’t have those numbers of how many patients
required it.
Dr Antoon Lerut (Leuven, Belgium). Over the recent years,
there has been a focus of interest on the relation between reflux
and BOS. Have you seen in your last cohort of patients an impact
of your antireflux therapy, whether it’s medical or surgical, on the
incidence of BOS and did it made a difference?
Dr Kreisel. We haven’t analyzed this specifically, as far as I
know, but we have been far more liberal offering fundoplications
to patients on the waiting list and early fundoplications in patients
who underwent lung transplantation.
Dr Lerut. Can you give us an idea about the fraction of patients
who are receiving an antireflux operation nowadays?
Dr Kreisel. I don’t know the exact number, but we have been
fairly liberal with that.ery c January 2011
